Medically reviewed by Gagandeep Brar, MD Key Takeaways CMML is a rare form of leukemia that can cause extreme fatigue, easy ...

– Complete remission (CR) rate of 50% and overall response rate (ORR) of 66.7% in 18 evaluable patients with CMML treated with IO-202 in combination with azacitidine – – CR rate of 83.3% and ORR of ...

"We found that being treated at an academic center was associated with improved survival, suggesting that specialized care for CMML is an important aspect of treatment." — Douglas Tremblay, MD, Tisch ...

BOSTON, Dec. 9, 2024 /PRNewswire/ -- Solu Therapeutics, a biotechnology company pioneering therapies to eliminate disease-driving cells in cancer, immunology, and other therapeutic areas, today ...

Blood Cancer United, which was formerly known as the Leukemia & Lymphoma Society, has created a way for blood cancer patients ...

CURE sat down with Dr. Tanja A. Gruber of Stanford Medicine Children’s Health to discuss clinical trials in infant leukemia. Recent advancements have brought optimism when it comes to treating infant ...

Colorado physicians helped research a new treatment protocol for the most common form of childhood cancer that has “instantly” changed how doctors treat pediatric leukemia — and provided a ...